Nordea: Another Amylin-owner would have been stronger
Bristol-Myers Squibb’s acquisition of Amylin Pharmaceuticals will, according to Nordea, lead to a better marketing-machine, but the bank would have seen another international actor as a stronger owner.
Bristol-Myers Squibb has spent DKK 40 billion on Amylin, but the pharmaceutical group is not the strongest partner for the diabetes drug company. Sanofi would have been a better option.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
